Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suresh Durgam

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
International Clinical Psychopharmacology|October 15, 2019
OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult femalesMitchell F Brin, Suresh Durgam, Arlene Lum, et al.
International Clinical Psychopharmacology|May 31, 2021
Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trialsJohn M Kane, Suresh Durgam, Andrew Satlin, et al.
Journal of Affective Disorders|August 28, 2017
The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label studyTerence A Ketter, Gary S Sachs, Suresh Durgam, et al.
The American Journal of Psychiatry|September 27, 2017
Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I DisorderArmin Szegedi, Suresh Durgam, Mary Mackle, et al.
Psychopharmacology|November 4, 2016
Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension studySuresh Durgam, William M Greenberg, Dayong Li, et al.
International Clinical Psychopharmacology|May 25, 2017
Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trialsMichael E Thase, John Edwards, Suresh Durgam, et al.
The Journal of Clinical Psychiatry|April 6, 2016
Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorderSuresh Durgam, Willie Earley, Hua Guo, et al.
Journal of Clinical Psychopharmacology|June 16, 2015
Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical TrialJohn M Kane, Stephen Zukin, Yao Wang, et al.
Paediatric Drugs|July 28, 2016
Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose TrialRobert L Findling, Ronald L Landbloom, Mary Mackle, et al.
The Journal of Clinical Psychiatry|August 28, 2025
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 TrialSuresh Durgam, Willie R Earley, Susan G Kozauer, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
International Clinical Psychopharmacology|October 15, 2019
OnabotulinumtoxinA for the treatment of major depressive disorder: a phase 2 randomized, double-blind, placebo-controlled trial in adult femalesMitchell F Brin, Suresh Durgam, Arlene Lum, et al.
International Clinical Psychopharmacology|May 31, 2021
Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trialsJohn M Kane, Suresh Durgam, Andrew Satlin, et al.
Journal of Affective Disorders|August 28, 2017
The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label studyTerence A Ketter, Gary S Sachs, Suresh Durgam, et al.
The American Journal of Psychiatry|September 27, 2017
Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I DisorderArmin Szegedi, Suresh Durgam, Mary Mackle, et al.
Psychopharmacology|November 4, 2016
Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension studySuresh Durgam, William M Greenberg, Dayong Li, et al.
International Clinical Psychopharmacology|May 25, 2017
Effects of vilazodone on suicidal ideation and behavior in adults with major depressive disorder or generalized anxiety disorder: post-hoc analysis of randomized, double-blind, placebo-controlled trialsMichael E Thase, John Edwards, Suresh Durgam, et al.
The Journal of Clinical Psychiatry|April 6, 2016
Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorderSuresh Durgam, Willie Earley, Hua Guo, et al.
Journal of Clinical Psychopharmacology|June 16, 2015
Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical TrialJohn M Kane, Stephen Zukin, Yao Wang, et al.
Paediatric Drugs|July 28, 2016
Long-term Safety of Asenapine in Pediatric Patients Diagnosed With Bipolar I Disorder: A 50-Week Open-Label, Flexible-Dose TrialRobert L Findling, Ronald L Landbloom, Mary Mackle, et al.
The Journal of Clinical Psychiatry|August 28, 2025
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 TrialSuresh Durgam, Willie R Earley, Susan G Kozauer, et al.
Pageof 6